Lynparza (olaparib) — CareFirst (Caremark)

Initial criteria

• Treatment of BRCA2-altered uterine leiomyosarcoma as subsequent therapy when used as a single agent for advanced, recurrent, metastatic, or inoperable disease

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression

Approval duration

12 months